Enter Your Search:
Results 1-3 (3)
Go to page number:
Select a Filter Below
Biopreservation and Biobanking (1)
Stem Cells and Development (1)
Transfusion medicine reviews (1)
Reems, Jo-Anna (3)
Sun, Sijie (3)
Ding, Weiping (1)
Gao, Dayong (1)
Gilligan, Diana M. (1)
Pineault, Nicolas (1)
Shu, Zhiquan (1)
Tseng, Hsiu-Yang (1)
Wang, Wenjing (1)
Wu, Xiaoping (1)
Year of Publication
Did you mean:
Distinct Functional Effects for Dynamin 3 During Megakaryocytopoiesis
Gilligan, Diana M.
Stem Cells and Development
Dynamin 3 (DNM3) is a member of a family of motor proteins that participate in a number of membrane rearrangements such as cytokinesis, budding of transport vesicles, phagocytosis, and cell motility. Recently, DNM3 was implicated as having a role in megakaryocyte (MK) development. To further investigate the functional role of DNM3 during megakaryocytopoiesis, we introduced sequence-specific short hairpin RNAs (shRNAs) into developing MKs. The results showed that knockdown of DNM3 inhibited a stage of MK development that involved progenitor amplification. This was evident by significant decreases in the number of colony forming unit-megakaryocytes, the total number of nucleated cells, and the number of CD41+ and CD61+ MKs produced in culture. Using a styrl membrane dye to quantify the demarcation membrane system (DMS) of terminally differentiated MKs, we found that DNM3 co-localized with the DMS and that DNM3 lentiviral shRNAs precluded the formation of the DMS. Knockdown of dynamin 3 in murine MKs also caused a decrease in the number of morphologically large MKs and the overall size of large MKs was decreased relative to controls. MK protein lysates were used in overlay blots to show that both DNM3 and actin bind to nonmuscle myosin IIA (MYH9). Consistent with these observations, immunofluorescence studies of MKs and proplatelet processes showed co-localization of DNM3 with MYH9. Overall, these studies demonstrate that DNM3 not only participates in MK progenitor amplification, but is also involved in cytoplasmic enlargement and the formation of the DMS.
A Microfluidic Study of Megakaryocytes Membrane Transport Properties to Water and Dimethyl Sulfoxide at Suprazero and Subzero Temperatures
Biopreservation and Biobanking
Megakaryocytes (MKs) are the precursor cells of platelets. Cryopreservation of MKs is critical for facilitating research investigations about the biology of this important cell and may help for scaling-up ex-vivo production of platelets from MKs for clinical transfusion. Determining membrane transport properties of MKs to water and cryoprotectant agents (CPAs) is essential for developing optimal conditions for cryopreserving MKs. To obtain these unknown parameters, membrane transport properties of the human UT-7/TPO megakaryocytic cell line were investigated using a microfluidic perfusion system. UT-7/TPO cells were immobilized in a microfluidic system on poly-D-lysine-coated glass substrate and perfused with various hyper-osmotic salt and CPA solutions at suprazero and subzero temperatures. The kinetics of cell volume changes under various extracellular conditions were monitored by a video camera and the information was processed and analyzed using the Kedem–Katchalsky model to determine the membrane transport properties. The osmotically inactive cell volume (Vb=0.15), the permeability coefficient to water (Lp) at 37°C, 22°C, 12°C, 0°C, −5°C, −10°C, and −20°C, and dimethyl sulfoxide (DMSO; Ps) at 22, 12, 0, −10, −20, as well as associated activation energies of water and DMSO at different temperature regions were obtained. We found that MKs have relatively higher membrane permeability to water (Lp=2.62 μm/min/atm at 22°C) and DMSO (Ps=1.8×10−3 cm/min at 22°C) than most other common mammalian cell types, such as lymphocytes (Lp=0.46 μm/min/atm at 25°C). This information could suggest a higher optimal cooling rate for MKs cryopreservation. The discontinuity effect was also found on activation energy at 0°C–12°C in the Arrhenius plots of membrane permeability by evaluating the slope of linear regression at each temperature region. This phenomenon may imply the occurrence of cell membrane lipid phase transition.
In Vitro Megakaryocyte Production and Platelet Biogenesis: State of the Art
Transfusion medicine reviews
The exciting and extraordinary capabilities of stem cells to proliferate and differentiate into numerous cell types not only offers promises for changing how diseases are treated, but may also impact how transfusion medicine is practiced in the future. The possibility of growing platelets in the laboratory to some day supplement and/or replace standard platelet products has clear advantages for blood bank centers and patients. Due to the high utilization of platelets by patients undergoing chemotherapy or receiving stem cell transplants, platelet transfusion has steadily increased over the past decades. This trend is likely to continue as the number of adult and pediatric patients receiving stem cell transplants is also continuously rising. As a result of increased demand coupled with the short shelf-life of platelet concentrates, providing platelets to patients can stretch the resources of most blood centers, drive donor recruitment efforts, and on occasion platelet shortages can compromise the care of thrombocytopenic patients.
The purpose of this article is to review current scientific progress to develop in vitro strategies to manufacture platelets, with an emphasis on efforts to produce functional platelets in quantities that would be required for clinical transfusion. There are a number of publications indicating that human platelets can be obtained in vitro from the controlled differentiation of hematopoietic stem cells. However, the hemostatic quality of such manufactured platelets has not been confirmed and current technologies are inadequate to ensure satisfactory expansion and platelet biogenesis on an industrial scale. Nonetheless, these studies provide proof-of-principle that developing in vitro strategies to manufacture platelets is feasible and also provide a foundation for developing more sophisticated approaches to achieve this goal.
Megakaryocyte; Stem cells; Megakaryocytopoiesis; Thrombocytopoiesis; ex vivo cultures; Platelet; Platelet biogenesis; Hematopoiesis
Results 1-3 (3)
Go to page number:
Remove citation from clipboard
Add citation to clipboard
This will clear all selections from your clipboard. Do you wish proceed?
Clipboard is full! Please remove an item and try again.
PubMed Central Canada is a service of the
Canadian Institutes of Health Research
(CIHR) working in partnership with the National Research Council's
Canada Institute for Scientific and Technical Information
in cooperation with the
National Center for Biotechnology Information
U.S. National Library of Medicine
(NCBI/NLM). It includes content provided to the
PubMed Central International archive
by participating publishers.